A Single Arm Open-Label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-Line Treatment of Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Trial Profile

A Single Arm Open-Label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-Line Treatment of Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms HAX
  • Sponsors Roche
  • Most Recent Events

    • 23 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by the ClinicalTrials.gov record.
    • 19 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top